title: Apoptotic activities in soft tissue sarcoma: immunohistochemical study and their association with tumour characteristics.
abstract: BACKGROUND
  Many studies on the role of apoptosis in cancer development and management have been undertaken. Apoptotic activity depends partly on the balance between anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) activities. This study compared Bcl-2 and Bax expression in the tumour cells and endothelial cells of tumour blood vessels in soft tissue sarcoma, and examined the association of these with tumour characteristics.
  
  
  METHODS
  A cross sectional (retrospective) study was conducted on 101 cases of various types of soft tissue sarcoma tumour cells and endothelial cells of tumour blood vessels. The immunohistochemical expressions of Bcl-2 and Bax were compared by correlating them according to site, size, depth, tumour margin, lymph node involvement, and histological type.
  
  
  RESULTS
  Higher Bax than Bcl-2 expression in tumour cells was observed, although the difference was not statistically significant. There was a significant direct association between Bcl-2 and Bax in tumour cells with endothelial cells. Among tumour characteristics, the only significant correlation was that of the Bcl-2 expression in tumour cells with tumour histological subtypes (synovial sarcoma and leiomyosarcoma).
  
  
  CONCLUSIONS
  The findings in this study support the role of endothelial cells in the survival and regression of tumour cells in tumour genesis. Therefore, inhibition of endothelial cell survival and activation, or induction of tumour cell apoptosis offers a promising prospect for tumour management.
authors: Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
authors: Thin Thin
authors: TT
authors: Win
authors: Yusri
authors: Y
authors: Yusuf
authors: Hasnan
authors: H
authors: Jaafar
keywords: Apoptosis; Bax; Bcl-2; soft tissue sarcoma
references: Virchows Arch. 1997 Jan;430(1):17-22
references: 9037310
references: Jpn J Clin Oncol. 1998 Feb;28(2):86-91
references: 9544821
references: Cell Growth Differ. 2000 Aug;11(8):437-45
references: 10965848
references: Cancer Lett. 2002 Apr 25;178(2):167-74
references: 11867201
references: Int J Cancer. 1998 Feb 20;79(1):13-8
references: 9495351
references: Cell Tissue Res. 2000 Jul;301(1):143-52
references: 10928287
references: Cancer Res. 1995 Oct 1;55(19):4471-8
references: 7671262
references: J Drug Target. 2002 Nov;10(7):529-33
references: 12683719
references: Clin Cancer Res. 1999 Feb;5(2):319-24
references: 10037180
references: J Clin Invest. 1999 Jan;103(2):159-65
references: 9916127
references: Oncol Rep. 1999 Sep-Oct;6(5):959-64
references: 10425286
references: Science. 1998 Aug 28;281(5381):1322-6
references: 9735050
references: Blood. 2003 Aug 1;102(3):964-71
references: 12689940
references: Cell. 1995 Jan 27;80(2):285-91
references: 7834748
references: Hum Pathol. 1996 Oct;27(10):1060-5
references: 8892591
references: Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):64-9
references: 17536310
references: Histopathology. 1996 Aug;29(2):159-63
references: 8872150
references: Cell. 1994 Oct 21;79(2):189-92
references: 7954787
references: Oncology. 1997 May-Jun;54(3):238-44
references: 9143406